FDA pushes forward on gene-editing therapies with new safety roadmap

Genome editing holds extraordinary promise for treating previously incurable genetic diseases

Lupin subsidiary settles US antitrust case with Humana for $30 Million

The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal

Aurobindo Pharma bags USFDA nod for Glycerol Phenylbutyrate Oral Liquid

The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics

Rusan Pharma secures Japan PMDA GMP approval for API, FDF facilities

PMDA is regarded among the most stringent regulatory bodies globally

Aurobindo Pharma wins USFDA nod for rare disease drug set for immediate launch

NHA convenes Chintan Shivir to accelerate Ayushman Bharat schemes

Focus on preventive, tech-driven healthcare and digital ecosystem reforms under AB PM-JAY and ABDM

Cipla receives two observations following USFDA inspection at Goa facility

The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe

NIFTY Pharma shows stable trend amid cautious market sentiment

Muted movement reflects consolidation phase as investors await earnings triggers

India pushes policy action on adolescent nutrition as obesity concerns rise

ICMR-led consultation calls for stricter HFSS regulations, nutrition literacy, and healthier food environments

Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection

Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions